Creative Biolabs is a contract research organization specialized in offering customized services for the development of antibodies for use in diagnostics, drug discovery, and basic research. Especially, we provide the expertise and personnel to offer high-quality in vitro diagnostic (IVD) antibody development services targeting a wide range of high-value diagnostic biomarkers to our clients. Here, we introduce our IVD antibody development services for CTAPIII marker.

Connective Tissue-Activating Peptide III (CTAPIII)

Connective Tissue-Activating Peptide III (CTAPIII) is well known in the art and also known as low-affinity platelet factor-4. Fragments or variants of CTAPIII protein are modified forms of CTAPIII protein or forms in which one, two, three, four or more amino acids has been changed, deleted, added, substituted or otherwise modified. In particular fragments or variants include truncated fragments and variants in which 1, 2, 3, 4 or more amino acids have been removed from the N-terminal end of the peptide. Specific fragments include a fragment in which 4 amino acids have been removed from the N-terminal end of the peptide (β-thromboglobulin) and a fragment in which 2 amino acids have been removed from the N-terminal end of the peptide.

Structure of the CTAPIII protein. Fig.1 Structure of the CTAPIII protein.

CTAPIII Marker of Osteoarthritis

A decreased concentration of CTAPIII protein or fragments, variants or degradation products can be used as a marker of osteoarthritis. CTAPIII is significantly lower in the osteoarthritis patients’ population compared to control subjects, and among osteoarthritis subsets, CTAPIII remains significantly reduced in osteoarthritis patients with the worst radiographic disease. CTAPIII has significant correlations with clusters of parameters reflecting the decline in cartilage metabolism, in local inflammation and the continuous bone remodeling as osteoarthritis progresses. Marker CTAPIII protein is particularly associated with the more advanced forms of osteoarthritis. Accordingly, the presence of a decreased amount of CTAPIII protein may be used to diagnose advanced osteoarthritis.

IVD Antibody Development Services for CTAPIII Marker

IVD antibodies are essential elements of commercial antibody-based in vitro diagnostic kits. Creative Biolabs has built an IVD platform for not only the development of high-quality antibodies for diagnostic use but also antibody & antigen conjugation and IVD kit development. Thus, we can help develop polyclonal, monoclonal, and recombinant antibodies against CTAPIII to aid in the development of IVD kits based on different immunoassay formats, such as latex-enhanced immunoturbidimetry, lateral flow immunochromatographic assays, and ELISA.

Supported by our highly specialized scientists and advanced platform, we are confident in providing services with the best quality and the most competitive prices. If you are interested in our services, contact us for more information.

Online Inquiry

*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828
Follow us on:
Copyright ©2011 - 2020 Creative Biolabs.